secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000950170-22-014426
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q2 core lung diag revenue $7.3M (+52% YoY); net loss $15.8M; reaffirms 2022 guidance
--------------------------------------------------------------------------------

- Core lung diagnostic revenue $7.3M, up 52% YoY; total revenue $11.0M down 8% due to COVID test decline.
- Net loss $15.8M, up 39% driven by loss on extinguishment from Indi contingent consideration restructuring.
- Cash and equivalents $28.7M (incl. $5.1M restricted); raised net $27.3M in debt/equity during Q2.
- Reaffirmed 2022 revenue outlook of $37.5M-$39.5M; Medicare coverage secured for Nodify CDT test.
- Announced strategic pacts with Philips, MSK, and Bio-Rad to co-develop an MRD test for solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022014426/0000950170-22-014426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022014426/bdsx-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-014426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer